CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Inc. COP Y/Y Annual
Fibrogen Inc   (NASDAQ: FGEN)
Other Ticker:  
 
 

FGEN's Income from Cont. Operations Growth by Quarter and Year

Fibrogen Inc 's Income from Cont. Operations results by quarter and year

 



FGEN Income from Cont. Operations (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December - -87.54 -56.23 -66.18
3rd Quarter September - -17.08 -63.62 -91.65
2nd Quarter June - -15.54 -87.68 -72.62
1st Quarter March -16.77 -32.93 -76.71 -63.21
FY   -16.77 -153.09 -284.24 -293.66

FGENs Annual Income from Cont. Operations
Fibrogen Inc 's Income from Cont. Operations in the fiscal year 2024 $ -153.10 millions
Fibrogen Inc 's Income from Cont. Operations in the fiscal year 2023 $ -284.23 millions
Fibrogen Inc 's Income from Cont. Operations in the fiscal year 2022 $ -293.65 millions
Fibrogen Inc 's Income from Cont. Operations in the fiscal year 2021 $ -290.02 millions
Fibrogen Inc 's Income from Cont. Operations in the fiscal year 2019 $ -76.97 millions




FGEN Income from Cont. Operations first quarter 2025 Y/Y Growth Comment
Fibrogen Inc in the first quarter 2025 recorded loss from continued operations of $ -16.77 millions.

According to the results reported in the first quarter 2025, Fibrogen Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Fibrogen Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the first quarter 2025.


FGEN Income from Cont. Operations ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Fibrogen Inc 's first quarter 2025 Income from Cont. Operations $ -16.77 millions FGEN's Income Statement
Fibrogen Inc 's first quarter 2024 Income from Cont. Operations $ -32.93 millions Quarterly FGEN's Income Statement


FGEN Income from Cont. Operations (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -


Current FGEN Income Statement >> Back to FGEN Growth rate Comparisons >>


Income from Cont. Operations first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Fibrogen Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FGEN's I. Quarter Q/Q Income from Cont. Operations Comment
Although Fibrogen Inc in the I. Quarter 2025 admitted loss from continued operations of $ -16.77 millions, it should be said, that this show slight up side in contrast to the -87.54 millions in the fourth quarter.

Within Major Pharmaceutical Preparations industry Fibrogen Inc achieved highest sequential Income from Cont. Operations growth. While Fibrogen Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FGEN's I. Quarter Q/Q Income from Cont. Operations Comment
Despite the fact, that Fibrogen Inc in the I. Quarter 2025 revealed loss from continued operations of $ -16.77 millions, it should be point out, that this show recovery compare to the -87.54 millions in the fourth quarter.

Within Major Pharmaceutical Preparations industry Fibrogen Inc achieved highest sequential Income from Cont. Operations growth. While Fibrogen Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Fibrogen Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)
Cumulative Income from Cont. Operations 12 Months Ending $ -136.93 $ -153.10 $ -121.79 $ -168.32 $ -240.46
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #


Cumulative Income from Cont. Operations growth Comment


Fibrogen Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment


Fibrogen Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
FGEN's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for FGEN's Competitors
Income from Cont. Operations Growth for Fibrogen Inc 's Suppliers
Income from Cont. Operations Growth for FGEN's Customers

You may also want to know
FGEN's Annual Growth Rates FGEN's Profitability Ratios FGEN's Asset Turnover Ratio FGEN's Dividend Growth
FGEN's Roe FGEN's Valuation Ratios FGEN's Financial Strength Ratios FGEN's Dividend Payout Ratio
FGEN's Roa FGEN's Inventory Turnover Ratio FGEN's Growth Rates FGEN's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Mar 31 2025
Pfizer Inc-4.96%$ -4.955 millions
Abbvie Inc -6.05%$ -6.050 millions
Incyte Corporation-6.69%$ -6.691 millions
Labcorp Holdings Inc -6.70%$ -6.702 millions
Mettler Toledo International Inc-7.84%$ -7.843 millions
National Research Corporation-9.00%$ -8.995 millions
Progyny Inc -10.88%$ -10.883 millions
Align Technology inc -11.23%$ -11.233 millions
Iqvia Holdings Inc -13.54%$ -13.542 millions
Ani Pharmaceuticals Inc-13.87%$ -13.874 millions
Steris Plc-14.71%$ -14.714 millions
Stryker Corp-17.01%$ -17.005 millions
Carlisle Companies Incorporated-18.02%$ -18.022 millions
Embecta Corp -18.69%$ -18.685 millions
West Pharmaceutical Services Inc -22.12%$ -22.116 millions
Mimedx Group Inc -22.49%$ -22.492 millions
Utah Medical Products Inc-23.13%$ -23.129 millions
Envista Holdings Corporation-23.73%$ -23.729 millions
Davita Inc -24.11%$ -24.107 millions
Corcept Therapeutics Inc-26.26%$ -26.263 millions
Dexcom Inc -28.01%$ -28.005 millions
Insulet Corporation-31.26%$ -31.262 millions
Select Medical Holdings Corp-36.22%$ -36.218 millions
Biogen Inc -38.87%$ -38.866 millions
Vertex Pharmaceuticals Inc-41.22%$ -41.224 millions
Amphastar Pharmaceuticals Inc -41.44%$ -41.439 millions
Solventum Corporation-42.19%$ -42.194 millions
Alkermes Plc -42.32%$ -42.323 millions
Becton Dickinson And Company-42.64%$ -42.644 millions
Lantheus Holdings Inc -44.34%$ -44.345 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com